5-MeO-DMT nasal spray Phase 2b: 26% remission at 8mg in 193-patient trial
prasanna_says · x · 2026-10-28
Phase 2b results for a 5-MeO-DMT nasal spray (BPL-003, mebufotenin) show single-dose treatment plus therapy in 193 patients with treatment-resistant depression.
- 26% of the 8mg group were in remission at day 29, vs 8% on 0.3mg
- Improvements persisted 8 weeks later
- Most patients were ready for discharge within two hours of dosing
A notable data point for psychedelic-assisted therapy.
More from AGI Musings
- Coding matters less than problem-finding: the shift from code engineers to product engineers — CtrlAltDwayne · 2026-10-28
- Rachel Thomas points to classic paper on articulating the value of not building tech — math_rachel · 2026-10-28
- Hypothetical $2T Anthropic IPO framed as channeling $100B+ a year into the real economy — sanjaykalra · 2026-10-28
- Biotech CEO: drug discovery will lag in the AI revolution, not lead it — vaibhavbetter · 2026-10-28
- AI cyber-wreckage noise far outstrips actual damage so far, argues new analysis — timigod · 2026-10-28
- 'Enjoy the low-polygon era': F-117 meme captures today's AI constraints — willcb · 2026-10-28